NEWS
TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial
TC BioPharm (NASDAQ: TCBP) has announced significant progress in its ACHIEVE Phase 2b clinical trial for TCB008, an allogeneic gamma-delta T cell therapy for cancer. The trial, focusing on patients with AML or MDS/AML, has reached a important milestone with the first patient completing the full dose regimen of approximately one billion cells. Importantly, no TCB008-related adverse events have been observed in any of the restart patients.
Key highlights include:
6 patients received a second dose
3 patients received a third dose
1 patient received a fourth dose
3 more patients expected to complete the full regimen by September's end
The company anticipates enrolling 24 patients in Cohort A and expects to announce a full data set, including primary and secondary endpoints, in the first half of 2025.
Key highlights include:
6 patients received a second dose
3 patients received a third dose
1 patient received a fourth dose
3 more patients expected to complete the full regimen by September's end
The company anticipates enrolling 24 patients in Cohort A and expects to announce a full data set, including primary and secondary endpoints, in the first half of 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1400Followers
79Following
10KVisitors
Follow